Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have gone in and out of this three times. Bought in a week ago at $40 and out today at $45.50.
If I am wrong on and it keeps going up I'm on to the next one...If it drops back I may buy back in.
Is it disruptive mind blowing tech or is it an accounting scam? I'm not sure. But it sure seems to be a good trading stock.
Alacrastores does not seem to offer them anymore. That is where I used to buy them.
Power back on yea! We at a $1.00 a share yet?
I'm 25 minutes west of the plant. Most businesses are closed today and tomorrow. Except of course Home Depot!
We seem to be missing the brunt of it. We'll see 30-40 mph winds w some 60 mph gusts.
You funny! I know the answer already. :-0
Dr. L:
How many employees does Novel have?
Hike
Hope ELTP is hit # 4257 for ya!
Well....I would argue there is some difference between "pure speculation/wild-ass guess" and "reasoned projection based on available data".
The difference may be that I actually have money invested here.
The difference may be that I actually picked up the phone and talked to people. The difference may be that I actually got off my behind and did some research. The difference may be that I laid out my reasoning in detail.
As my Dad would say. "Behold the turtle, he only makes progress when he sticks his neck out."
Reduction in costs due to less payments for dividends preferred shareholders and reduced costs of production. I didn't say probable, just allowing for the possible.
Not the quarter they are about to report but it will suppress growth somewhat for the current quarter onward.
They have rolled out four drugs since last year. Sales ramp up.
The consensus among longs is a 20% increase over last quarter.
Better. Possibly a profitable quarter.
About 11/15
http://www.fool.com/investing/general/2012/10/15/the-pain-of-developing-pain-drugs.aspx
The Pain of Developing Pain Drugs
By Brian Orelli | More Articles
October 15, 2012 | Comments (0)
Pfizer (NYSE: PFE ) released data last week on its tamper-resistant pain killer, ALO-02. The phase 3 trial was an open-label, single-arm trial to measure safety, so we didn't learn much about the efficacy of the drug.
A whopping 60% of the patients dropped out of the study over the course of the year, including 19% of the patients that said adverse events were the primary reason for dropping out. Nausea, constipation, vomiting, and headaches were the most common issues. There were more serious adverse events reported, but they were so rare that they probably weren't drug related. Presumably the other 41% of patients that dropped out either felt the drug wasn't working, their pain symptoms stopped (although patients were supposed to have chronic pain), or experienced some issue unrelated to the drug.
What's interesting is that Pfizer said, "The discontinuation rate was within the expected range based on similar long-term safety studies with other extended-release opioid formulations." I have no reason not to believe the pharma, but it seems kind of shocking that a 60% dropout rate is the norm. How do you run a trial to measure how well your drug works when more than half the patients drop out before it's completed?
And for those that stay in the trial, drugmakers have to deal with the placebo effect affecting the results. Subjective patient-reported outcomes are very difficult to control.
There's clearly a large societal need for drugs like ALO-02 because it's designed to be harder to abuse. The Food and Drug Administration has supported the push to decrease abuse of pain drugs. And in theory developing tamper-resistant drugs is low risk too because they use active ingredients that have already been proven to work. The active ingredient in ALO-02, for instance, is oxycodone.
But given the issues with patient dropouts and placebo effect, investors should be cautious about investing in this space. For Pfizer, one drug isn't going to matter, but failures of pain drugs being developed by Zalicus and Pain Therapeutics could be disastrous as investors in Durect found out earlier this year.
Fair enough, as silly a comment as that was I will give the audience another way to look at it.
.8% of all outstanding shares were sold (and bought) today.
Hardly the panic of 1929...
Based on what I own I'd say about 3 or 4 people...WOW!!! LOL LOL
Yes, but why the heck would the FDA require all new approvals? Or does the FDA not regulate the API suppliers?
If a second supplier exists and that supplier is FDA?DEA approved why in the world would it take up to a year to qualify them? Phentermine HCL varied that much from supplier to supplier?
All things considered the sell off hasn't been that bad...so far.
Either this is in such demand that they are putting customers on allocation or elite is perceived as a credit risk and the supplier is minimizing their credit exposure. If not one of these two items then its malicious but good luck proving that or suing for it .
Lodrane all over again...
Fair to say a whole lotta Pharma experience there...giggle giggle
Ledgemont Capital Group
In a nutshell the suggestion is that doctors will prescribe the generic components in the appropriate ratio rather than the branded drug. It is much cheaper to do so among other advantages.
True:
Carter Ward was appointed as our Chief Financial Officer on July 1, 2009, and as our Secretary and Treasurer on August 13, 2009. Since June 2009, Mr. Ward has been engaged by Epic as a consultant and the services provided by Mr. Ward to Epic pursuant to such engagement include, but are not limited to, consulting on matters relating to the finances, business development and operations of Epic
The truth is worth a fuss
Nope it's with massive actavis too
The po's can come from actavis
Yes, Dr. L, Actavis is clearly not just mentioned in the last 10k, they are listed as a customer of Elite. You just need to make a tiny effort.
Under ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES.
The reference is made to:
10.70 Manufacturing & Supply Agreement between the Company and Mikah Pharma LLC, dated as of June 1, 2011, incorporated by reference to Exhibit 10.70 to the Annual Report on Form 10-K, for the period ended March, 31, 2011 and filed with the SEC on June 29, 2011 (Confidential Treatment granted with respect to portions of the Agreement).
As we all know this Agreement specifically identifies Actavis as a customer:
Within that agreement you will find:
3.4 Purchase Orders. Mikah or Actavis, Mikah’s designee, shall submit Purchase Orders for Product
So, Dr. L, Actavis is indeed in the latest 10k incorporated by reference. Sometimes you have to dig just a little deeper.
.20 is the big money?
I'm amazed no assault on my predictions. Must mean they are right on? Looking forward to the 63% return in five months!
Given the long time waited to get approval I think (IMHO) that Elite has had PO's in hand for some time. The November 10Q will show nice improvement but the Feb 2013 will show significant improvement.
Methinks PPS is
.135 by 10/30/2012 on heels of shipment PR's
.16 by 11/30/2012 following earnings
.18 by 2/28/2013
There, I said it.
By the way thanks to Laser's input the spreadsheet has been updated.
Would be nice!
774,000 shares on the ask?
Well bear in mind the previous 2 months were also revised upward. So the "net gain" is more like 200,000.
From Dianne:
This was last year’s materials.
It was brought to our attention by our SEC counsel that the OTCBB does not require that the Company hold an annual stockholder meeting unless, of course, there are matters that need to be brought before the stockholders to vote on.
At this time, it would just be a vote to reelect the Board of Directors and the ratification of the auditors.
For this reason, the Company will not hold a meeting until the time there are issues that need to be approved by the stockholders.
The good news is that this save the company SEVERAL THOUSANDS of $’s. Money that can be put to better use for drug development, etc.
Best regards,
Dianne.
Minor clarification..
It's for a an intermediate of a generic version of a $100,000,000 branded product.
So let's be a little more conservative. By years end HITK gets $10,000,000 in sales. So that might be $1,500,000 to Elite plus maybe $500,000 in manufacturing fees and milestones.
Still, this one product plus the products already in play will make ELTP profitable.
After 3 years this would probably triple/quadruple.
Read 10.77
It is the description of the HK deal with the name of the HK partner redacted pending approval of CT order (It says right in there they had filed for it).
So all this is about is that the SEC, "Yes, we agree you don't have to reveal your partners name in the 10k"
Nothing more than that.
The possibility existed in theory that the SEC could have turned down the CT order request and ELTP would have had to amend their 10k with the name of the HK partner.
What appears to have happened is the SEC said they (ELTP) had to disclose at least a little more detail, hence the amended 10k last week.